[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paroxysmal-atrial-fibrillation-paf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paroxysmal-atrial-fibrillation-paf":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,66,97,129,164,191,215,239,256,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100625318","grid-explore-mapping-study-100625318",false,"NCT07421076","Grid eXplore Mapping Study","Inclusion Criteria:\n\n1. Subject must provide written informed consent prior to any clinical investigation-related procedure.\n2. Subject is at least 18 years of age.\n3. Documented symptomatic paroxysmal AF, defined as:\n\n   * Physician's note indicating self-terminating AF AND\n   * Electrocardiographically documented AF NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device.\n4. Subject plans to undergo a cardiac electroanatomic mapping and ablation procedure to treat their paroxysmal AF.\n5. Able and willing to comply with all trial requirements including pre-procedure, post-procedure, and follow-up testing and requirements\n\nExclusion Criteria:\n\n1. Primary diagnosis or indication for treatment of persistent or long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)\n2. Known presence of cardiac thrombus.\n3. Known existing circumferential pericardial effusion \\>2 mm prior to catheter insertion.\n4. Presence of any condition that precludes appropriate vascular access\n5. Implanted intracardiac device within 30 days prior to the procedure\n6. Pregnant or nursing\n7. Patients who have had a ventriculotomy or atriotomy within 28 days prior to the procedure\n8. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days\n9. Stroke or TIA (transient ischemic attack) within the last 90 days\n10. History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti-coagulant state\n11. Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation\n12. Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication\n13. Previous left atrial surgical procedure (including left atrial appendage (LAA) closure device)\n14. Severe mitral regurgitation (regurgitant volume ≥ 60 mL\u002Fbeat, regurgitant fraction ≥ 50%, and\u002For effective regurgitant orifice area ≥ 0.40cm2)\n15. Previous tricuspid or mitral valve replacement or repair\n16. Patients with prosthetic valves\n17. Patients with a myxoma\n18. Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt\n19. Stent, constriction, or stenosis in a pulmonary vein\n20. Rheumatic heart disease\n21. Hypertrophic cardiomyopathy\n22. Active systemic infection\n23. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms\n24. Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from this study Sponsor\n25. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.\n26. Individuals without legal authority\n27. Individuals unable to read or write","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of the trial is to find out if the Grid X Mapping Catheter and EnSite X EP System with EnSite X Software v3.1.1, the devices that are being studied, are safe and effective in treating Chinese patients who have atrial fibrillation.\n\nParticipants will receive a procedure called catheter mapping and ablation to treat their abnormal heart rhythms and are required to complete 4 follow-up visits at 7 days, 3 months, 6 months and 12 months after the procedure for checkups and tests.",[25],"Paroxysmal Atrial Fibrillation (PAF)",[27],"Paroxysmal atrial fibrillation","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"2026-04-02",{"date":36,"type":19},"2027-10-31",{"name":38,"class":39},"Abbott Medical Devices","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100639755","evaluation-of-the-faraflex-mapping-and-pulsed-field-ablation-system-in-subjects-with-atrial-fibrillation-100639755","NCT07575269","Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation","Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation - A Global Prospective Single Arm Study","FARADIGM","Inclusion Criteria:\n\n1. At least 18 years old (or older if required by local law)\n2. Symptomatic, documented, drug-refractory paroxysmal or persistent atrial fibrillation (AF).\n3. Willing and capable of providing written informed consent\n4. Willing and able to comply with all follow-up assessments and study procedures at an approved investigational site\n\nExclusion Criteria:\n\n1. Any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter of at least 5.5 cm, or if not available, non-indexed volume greater than 100 mL\n   2. Any prior atrial endocardial, epicardial, or surgical ablation for atrial arrhythmia (excluding right-sided Supraventricular Tachycardia (SVT) or Cavo-Tricuspid Isthmus (CTI)-dependent flutter)\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Pulmonary vein abnormality, stenosis, or prior stenting (common and middle pulmonary veins allowed)\n   6. Current left atrial thrombus\n2. Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia or ventricular fibrillation\n   2. Atrial fibrillation secondary to reversible or non-cardiac causes (e.g., electrolyte imbalance, thyroid disease, alcohol)\n   3. Presence of any of the following cardiac devices or implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy device\n      * Current implantable loop recorder other than LUX-Dx\n      * Prior interatrial baffle or septal closure device\u002Fpatch (Patent Foramen Ovale (PFO)or Atrial Septal Defect (ASD))\n      * Left atrial appendage closure or occlusion device\n   4. Clinically significant valvular disease, including:\n\n      * Any cardiac valve prosthesis, ring, repair, or clip\n      * Moderate to severe mitral stenosis\n      * Moderate to severe aortic stenosis\n      * Severe mitral regurgitation\n      * Severe tricuspid regurgitation\n   5. Hypertrophic or amyloid cardiomyopathy\n   6. Presence of Inferior Vena Cava (IVC) filter, inability to obtain vascular access, or contraindication to femoral access\n   7. Awaiting cardiac transplantation or other cardiac surgery within 12 months (left atrial appendage closure\u002Focclusion procedures allowed no less than (≥) 60 days after index procedure)\n   8. Severe right ventricular dysfunction per investigator assessment\n3. Any of the following congenital conditions:\n\n   1. Congenital heart disease with clinically significant residual anatomic or conduction abnormalities, or channelopathies\n   2. Known congenital methemoglobinemia\n   3. Known G6PD deficiency\n4. Any of the following medical history conditions:\n\n   1. Solid organ or hematologic transplant, or under evaluation for transplant\n   2. History or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Prinzmetal angina or severe non-revascularizable coronary disease\n   4. Known coagulopathy or bleeding disorder\n   5. Renal insufficiency, history of dialysis, or renal transplant\n   6. Known allergic reaction to nitroglycerin (excluding hypotension)\n   7. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure\n   8. Active spinal cord stimulator\n5. Any of the following baseline conditions:\n\n   1. NYHA Class III or IV heart failure\n   2. Left ventricular ejection fraction (LVEF) less than 40% within 12 months\n   3. CHA2DS2-VASc score greater than or equal to 5\n   4. Body mass index (BMI) greater than 45.0\n   5. Contraindication to or unwillingness to use systemic anticoagulation peri-procedurally\n   6. Pregnant or lactating at time of procedure\n   7. Severe lung disease, pulmonary hypertension, or oxygen-dependent lung disease\n   8. Active malignancy (excluding squamous cell carcinoma)\n   9. Clinically significant gastrointestinal disease (e.g., severe or erosive esophagitis, uncontrolled reflux, gastroparesis, esophageal candidiasis, active gastroduodenal ulceration)\n   10. Known Active systemic infection\n   11. Life expectancy of less than 1 year\n   12. Concurrent enrollment in another investigational study or registry that may interfere with this study (exceptions include mandatory governmental registries or purely observational registries with sponsor approval)\n6. Any of the following events within 90 days prior to consent:\n\n   1. Myocardial infarction, unstable angina, or coronary intervention\n   2. Pericarditis or symptomatic pericardial effusion\n   3. Gastrointestinal bleeding\n   4. Cardiac surgery\n   5. Stroke, Transient Ischemic Attack (TIA), or intracranial bleeding\n   6. Any active non-neurologic thrombus and\u002For thromboembolic event\n   7. Carotid stenting or endarterectomy\n   8. Heart failure hospitalization\n   9. Uncontrolled diabetes mellitus or HbA1c greater than 8.0%\n7. Other conditions:\n\n   1. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted ICM from the LUX-Dx family of devices\n   2. Any medical condition that, in the investigator's opinion, would interfere with study participation, increase risk, or affect data interpretation",{"count":50,"type":19},571,[22],"The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is:\n\nIs the FARAFLEX Mapping and PFA System a safe and effective treatment for patients?\n\nParticipants will undergo an ablation procedure using the FARAFLEX Mapping and PFA System.",[25,54],"Persistent Atrial Fibrillation",[56],"pulsed field ablation","2026-06-25",{"date":29,"type":32},{"date":60,"type":19},"2026-06-12",{"date":62,"type":19},"2030-01-01",{"name":64,"class":39},"Boston Scientific Corporation",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":65},"100636945","home-monitor-for-aa-burden-detection-iit-in-twn-100636945","NCT07572279","Home Monitor for AA Burden Detection IIT in TWN","The Clinical Follow-Up of the Amvia Pacemaker Family Using Atrial Anti-Tachycardia Pacing (aATP) and Home Monitoring Function in the Patients With Paroxysmal Atrial Fibrillation (PAF)","FF108","Inclusion Criteria:\n\n* Adult patients ≥ 20 years of age\n* Diagnosed with Paroxysmal Atrial Fibrillation (PAF) or atrial flutter who have been implanted or planned to implant with permanent pacemaker device\n* The diagnosis of AF is confirmed on a 12-lead electrocardiogram (ECG) or lasting \\>30 seconds in single lead ECG monitor\n* Implanted within 12 weeks prior to enrollment or being considered for implantation of a PPM with Home Monitoring technology\n* Able to give informed consent for the participation in the trial\n\nExclusion Criteria:\n\n* Patients are not able to use CardioMessenger 4G or its successors\n* Life expectancy \\\u003C 1 year\n* Sepsis\n* Long-standing Persistent Atrial Fibrillation or Permanent Atrial Fibrillation\n* Pregnant or breast-feeding women\n* Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints\n* Participation in another prospective interventional clinical study within a period of 4 weeks prior to the implantation of Atrial Arrhythmia\n* Present or history of drug addiction\n* Any other condition that, in the investigator's judgment, might increase the risk to the patients or affect trial quality\n* Patients underwent implantable cardioverter-defibrillator implantation","20 Years",{"count":76,"type":19},30,"OBSERVATIONAL","Primary Endpoint:\n\n* Early detection rate in Atrial Arrhythmia (AA) burden\n* Data transmission success rate for overall number of atrial burden collection during the monitoring period\n\nSecondary Endpoints:\n\n* Atrial burden occurrence at 3\u002F6\u002F12 months post-aATP\n* Incidence of arrhythmia\n* Safety: Immediate (\\\u003C 24 hours), in-hospital, 3 months, 6 months and 12 months adverse events",[25,80],"Atrial Flutter",[82,83,84,85],"Paroxysmal Atrial Fibrillation","atrial flutter","permanent pacemaker device","Home Monitoring technology","NOT_YET_RECRUITING","2026-05-04",{"date":89,"type":32},"2026-05-07",{"date":91,"type":19},"2026-06-01",{"date":93,"type":19},"2030-12-31",{"name":95,"class":96},"National Taiwan University Hospital","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":20,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100638209","outcomes-of-an-optimized-workflow-with-pulseselect-pulsed-field-ablation-pfa-system-in-paroxysmal-and-persistent-atrial-fibrillation-100638209","NCT07575828","Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation","Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation (NEXT PULSE)","NEXT PULSE","Inclusion Criteria:\n\n1. Adults who are ≥18 and ≤80 years of age on the day of enrollment (or older than 18 if required by local law)\n2. A diagnosis of recurrent symptomatic paroxysmal or persistent AF:\n\n   Symptomatic paroxysmal AF: AF that terminates spontaneously or with intervention within 7 days of onset, documented by the following:\n   1. Physician's note indicating at least 2 symptomatic paroxysmal AF episodes occurring within 12 months prior to enrollment; AND\n   2. at least 1 ECG documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment.\n\n   Symptomatic persistent AF: Continuous AF sustained beyond 7 days and less than 1 year, documented by the following:\n   1. Physician's note indicating at least 1 symptomatic persistent AF episode occurring within 12 months prior to enrollment; AND\n   2. any 24-hour continuous ECG recording documenting continuous AF within 12 months prior to enrollment; OR 2 ECGs from any form of rhythm monitoring taken at least 7 days apart, both showing continuous AF within 12 months prior to enrollment\n3. Willing and able to comply with all baseline and follow-up evaluations for the full length of the study.\n\nExclusion Criteria:\n\n1. Long-standing persistent AF (continuous AF that is sustained \\>12 months)\n2. Paroxysmal AF patients: AF that required three (3) or more distinct cardioversions in the preceding 12 months.\n3. Paroxysmal AF: LA anteroposterior diameter \\> 5.0 cm (by MRI, CT, or TTE) Persistent AF: LA anteroposterior diameter \\> 5.5 cm (by MRI, CT, or TTE)\n4. Any of the following procedures, implants, or conditions at baseline: prior left atrial catheter or surgical ablation, prior left atrial percutaneous interventions including left atrial appendage occlusion, and septal closure devices\n5. Planned LAA closure procedure or implant of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period\n6. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)\n7. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure\n8. Contraindication to or unwillingness to use systemic anticoagulation\n9. Presence of any pulmonary vein stents\n10. Known pre-existing pulmonary vein stenosis\n11. Prior valvular (surgical or percutaneous) procedure including prosthetic, bioprosthetic, valve replacement, valve repair or valvuloplasty, and any prior atriotomy\n12. Moderate to severe mitral valve or aortic stenosis\n13. Moderate to severe mitral regurgitation (i.e., 3+ or 4+ MR)\n14. Any cardiac surgery, myocardial infarction, PCI \u002F PTCA or coronary artery stenting which occurred during the 3-month interval preceding the consent date\n15. Unstable angina\n16. NYHA Class III or IV congestive heart failure or documented left ventricular ejection fraction (LVEF) less than or equal to 40% measure by acceptable cardiac testing (e.g. TTE), or planned transplant or left ventricular assist device (LVAD)\n17. Severe lung disease, primary pulmonary hypertension, or any lung disease abnormal blood gases or requiring supplemental oxygen\n18. Rheumatic heart disease\n19. Severe thrombocytosis, thrombocytopenia, or any bleeding or clotting disorder\n20. Documented left atrial thrombus on imaging\n21. Active systemic infection or sepsis\n22. Hypertrophic cardiomyopathy\n23. Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity\n24. Any cerebral ischemic event (strokes or TIAs) which occurred during the 6-month interval preceding the consent date\n25. Carotid stenting or endarterectomy\n26. History of thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure\n27. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence\n28. Patient with life expectancy that makes it unlikely 12 months of follow-up will be completed\n29. Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre-approved by Medtronic\n30. Known allergies or hypersensitivities to adhesives\n31. Body mass index \\> 40 kg\u002Fm2\n32. Atrial myxoma\n33. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.\n34. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2, or any history of renal failure requiring dialysis or renal transplant\n35. Solid organ or hematologic transplant, or currently being evaluated for an organ transplant\n36. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation\n37. Known drug or alcohol dependency\n38. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would impact the scientific soundness of the clinical trial results\n39. Amyloid heart disease (cardiac amyloidosis)","80 Years",{"count":107,"type":19},320,[22],"The NEXT PULSE study is a pre-market, prospective, multi-center, non-randomized, interventional clinical study. Adult subjects with symptomatic paroxysmal or persistent AF who provided consent will be enrolled and treated with the PulseSelect PFA System.",[25,54],[112,113,114,115,116,117,118,119,120],"Atrial Fibrillation (AF)","Paroxysmal AF","Persistent AF","Symptomatic recurrent AF","Arrhythmia","PulseSelect PFA System","Pulsed Field Ablation","Catheter ablation","Pulmonary Vein Ablation",{"date":122,"type":32},"2026-05-08",{"date":124,"type":19},"2026-08",{"date":126,"type":19},"2029-03",{"name":128,"class":39},"Medtronic Cardiac Ablation Solutions",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":20,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":76},"100615889","conquer-af-protocol-for-redo-ablation-procedures-in-recurrent-paroxysmal-and-persistent-atrial-fibrillation-using-the-sphere-9-catheter-and-affera-ablation-system-conquer-af-100615889","NCT07298473","Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)","Conquer-AF","Inclusion Criteria:\n\n* 1\\. History of a single AF ablation procedure for PAF or PsAF within 3 years prior to enrollment 2. Documented evidence of symptomatic AF, AT or AFL recurrence at least 90 days after subject's de novo ablation procedure, as demonstrated by:\n\n  * A physicians' note indicating at least 1 symptomatic AF, AT, or AFL episode occurring within 12 months prior to the enrollment; and\n  * At least 1 electrocardiographically documented episode of AF, AT, or AFL within 12 months prior to enrollment 3. Adults who are ≥18 years of age on the day of enrollment 4. Willing and able to comply with all study requirements and provide informed consent\n\nExclusion Criteria:\n\n* 1\\. Continuous AF lasting for 12 months or longer 2. LA anteroposterior \\>55 mm (by MRI, CT, or TTE), or if LA diameter not available, non-index volume \\>100 mL for PsAF subjects; OR LA anteroposterior \\>50 mm (by MRI, CT, or TTE), or if LA diameter not available, non-index volume \\>95 mL for PAF subjects 3. Previous left atrial percutaneous interventions including left atrial appendage occlusion and septal closure devices 4. Planned left atrial appendage (LAA) closure procedure, cardiac transplantation or implant of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period 5. More than 1 previous AF ablation procedure 6. Any prior surgical ablation procedure 7. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure 8. Contraindication to or unwillingness to use systemic anticoagulation 9. Severe thrombocytosis, thrombocytopenia, or any bleeding or clotting disorder 10. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) 11. Presence of any pulmonary vein stents 12. Known pre-existing pulmonary vein stenosis 13. Pre-existing hemidiaphragmatic paralysis 14. Prior valvular (surgical or percutaneous) procedure including prosthetic, bioprosthetic, valve replacement, valve repair or valvuloplasty, or any prior atriotomy 15. Moderate to severe mitral valve or aortic stenosis 16. Moderate to severe mitral regurgitation (i.e., 3+ or 4+ MR) 17. Any cardiac surgery, myocardial infarction, PCI\u002FPTCA or coronary artery stenting which occurred within the 3 months preceding the consent date 18. NYHA Class III or IV congestive heart failure 19. Documented left ventricular ejection fraction (LVEF) ≤40%, measured by acceptable cardiac testing (e.g., TTE) 20. Unstable angina 21. Severe lung disease, primary pulmonary hypertension, or any lung disease requiring supplemental oxygen 22. Rheumatic heart disease 23. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition 24. Presence of left atrial thrombus on imaging 25. Active systemic infection or sepsis 26. Hypertrophic cardiomyopathy 27. Amyloid heart disease 28. Diagnosed atrial myxoma 29. Known reversible causes of AF (e.g., uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, acute alcohol toxicity or other reversible or non-cardiac cause) 30. Any cerebral ischemic event (strokes or TIAs) which occurred within the preceding 6 months of the consent date through the date of study index redo ablation procedure 31. Carotid stenting or endarterectomy 32. Thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure 33. Body mass index \\> 40 kg\u002Fm2 34. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence\\* 35. Patient with life expectancy that makes it unlikely 12 months of follow-up will be completed 36. Current or anticipated participation in any other clinical study of a drug, device or biologic during the duration of the study not pre-approved by Medtronic 37. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2, or any history of renal failure requiring dialysis or renal transplant 38. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation 39. Presence of an inferior vena cava (IVC) filter (e.g., Greenfield or similar) that would preclude safe transfemoral venous access, catheter passage, or sheath manipulation.\n\n  40\\. Known drug or alcohol dependency 41. Significant congenital anomaly or medical problem that would, in the opinion of the investigator, preclude enrollment, follow-up compliance, or the scientific integrity of the study\n\n  \\*Women who are of child-bearing potential must undergo a pregnancy test after consent and prior to the study index redo ablation procedure, as allowed according to local regulations",{"count":137,"type":19},400,[22],"Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia.\n\nSubjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.",[112,54,25],[142,143,144,145,146,147,148,82,54,149,150,151,152,153,154,155],"Sphere-9 Catheter","Affera Ablation System","Affera Mapping System","Pulsed Field Ablation (PFA)","Radiofrequency Ablation (RFA)","Dual-Energy Ablation","Atrial Fibrillation","Redo Ablation","Repeat Ablation","Electrophysiology Mapping","3D Cardiac Mapping","Left Atrial Ablation","Redo AF Ablation","Repeat Ablation Procedures","2026-04-09",{"date":158,"type":32},"2026-04-13",{"date":160,"type":32},"2026-04-08",{"date":162,"type":19},"2028-03-29",{"name":128,"class":39},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":172,"targetDuration":4,"studyType":20,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":65},"100607674","pulsed-field-ablation-of-svc-and-pv-in-paroxysmal-atrial-fibrillation-paspa-study-100607674","NCT07191626","Pulsed Field Ablation of SVC and PV in Paroxysmal Atrial Fibrillation (PASPA Study)","Pulsed Field Ablation of Superior Vena Cava in Addition to Pulmonary Vein in Paroxysmal Atrial Fibrillation: A Multicenter Randomized Controlled Trial (PASPA Study)","PASPA","Inclusion Criteria:\n\n1. Documented paroxysmal AF (episodes self-terminating within 7 days), evidenced by ECG, Holter, or event monitor\n2. Age between 18 and 80 years\n3. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Intracardiac thrombus (left atrium or left atrial appendage)\n2. Left atrial anterior-posterior diameter \\> 60 mm\n3. Absolute contraindication to anticoagulation therapy\n4. Stroke or myocardial infarction within 1 month prior to enrollment\n5. Uncontrolled hyperthyroidism\n6. Pregnancy or planning pregnancy\n7. Life expectancy less than 1 year\n8. Previous atrial fibrillation ablation procedure\n9. Known or suspected AF triggers primarily originating from the SVC (based on pre-procedure mapping, if available)\n10. Inability or unwillingness to participate in the study or comply with follow-up requirements",{"count":173,"type":19},650,[22],"The PASPA study is a multicenter, randomized trial comparing Pulmonary Vein Isolation (PVI) alone versus PVI plus Superior Vena Cava Isolation (SVCI) using Pulsed Field Ablation (PFA) in patients with paroxysmal atrial fibrillation (PAF).\n\n650 participants will be followed for 12 months. The main goal is to see if adding SVCI reduces arrhythmia recurrence without increasing complications such as phrenic nerve injury or sinus node dysfunction.",[82,25],[178,179,118,180,181],"Paroxysmal, Catheter Ablation","Catheter Ablation","Pulmonary Vein Isolation","Superior Vena Cava Isolation","2025-09-24",{"date":184,"type":32},"2025-09-25",{"date":186,"type":19},"2025-11-01",{"date":188,"type":19},"2027-11-01",{"name":190,"class":96},"Changhai Hospital",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":198,"targetDuration":4,"studyType":20,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100599078","clinical-study-on-the-efficiency-of-rapid-arrhythmia-mapping-using-easystars-high-density-mapping-catheter-applications-100599078","NCT07079813","Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications","Rapid Arrhythm","1. Clinical diagnosis: Ventricular tachycardia (VT)\n\n   * Inclusion criteria:\n\n     1. Patients aged between 18 and 80 years;\n     2. Confirmed diagnosis of ventricular tachycardia (VT) via electrocardiogram (ECG) or 24-hour Holter monitoring;\n     3. The patient has experienced at least one episode of VT in the past 6 months and exhibits symptoms of sustained or paroxysmal ventricular tachycardia;\n     4. The patient meets the criteria for ablation surgery and has clear indications for ablation;\n     5. The patient is in good general health and able to tolerate surgery (no severe underlying heart disease, such as severe heart failure or severe coronary artery disease);\n     6. Voluntarily participates and signs an informed consent form.\n   * Exclusion criteria:\n\n     1. Uncontrolled heart failure (New York Heart Association functional class III-IV);\n     2. History of acute or progressive myocardial infarction;\n     3. Severe pulmonary, hepatic, or renal disease;\n     4. Valvular heart disease or congenital heart disease;\n     5. Excessive use of medications or medication intolerance (e.g., beta-blockers, antiarrhythmic drugs);\n2. Clinical diagnosis: Atrial tachycardia (AT)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with atrial tachycardia (AT) by electrocardiogram (ECG) or Holter monitoring;\n     3. Patients presenting with clinical symptoms such as palpitations, chest tightness, or fatigue;\n     4. Patients diagnosed with persistent or paroxysmal atrial tachycardia and meeting the criteria for ablation therapy;\n     5. Patients who voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease or congenital heart disease;\n     2. Patients with severe left ventricular or right ventricular heart failure;\n     3. Patients with severe systemic diseases, such as liver failure, kidney failure, or tumours;\n     4. Patients with cardiomyopathy or aortic dissection;\n3. Clinical diagnosis: atypical atrial flutter (AFL)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Patients diagnosed with atypical atrial flutter (AFL) via electrocardiogram (ECG) or Holter monitoring;\n     3. Patients with clinical symptoms (e.g., palpitations, chest tightness, fatigue, etc.) that significantly impair their quality of life;\n     4. Patients who meet the criteria for atrial tachycardia ablation and have no other severe comorbidities;\n     5. Voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe heart disease, such as cardiomyopathy or severe valvular disease;\n     2. Patients with severe pulmonary disease, such as pulmonary arterial hypertension;\n     3. Patients with a history of major cardiac surgery (e.g., heart transplantation);\n4. Clinically diagnosed with paroxysmal atrial fibrillation (PAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with paroxysmal atrial fibrillation (PAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Frequent episodes of paroxysmal atrial fibrillation with symptoms such as palpitations, fatigue, and dyspnoea, and meeting the criteria for ablation;\n     4. No other severe cardiac or systemic diseases, and meeting the criteria for ablation;\n     5. Voluntarily participating and signing the informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease, aortic dissection, or cardiomyopathy;\n     2. High-risk patients with a history of anticoagulant therapy or currently receiving anticoagulant therapy (e.g., history of thrombosis or stroke);\n     3. Patients with severe underlying conditions such as cancer or severe diabetes;\n5. Clinical diagnosis: Persistent atrial fibrillation (PsAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with persistent atrial fibrillation (PsAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Atrial fibrillation persisting for more than 7 days and symptoms affecting the patient's quality of life;\n     4. Clear indications for ablation and no other severe comorbidities;\n     5. Voluntarily participating and signing an informed consent form.\n\nExclusion criteria:\n\n1. Presence of severe valvular heart disease or cardiomyopathy;\n2. History of stroke or clinical evidence of thrombus formation;\n3. Severe heart failure (NYHA III-IV class);\n4. High-risk cardiac conditions (e.g., acute myocardial infarction, coronary artery disease); In the above different types of rapid arrhythmias, the inclusion criteria primarily focus on the diagnosis and control of clinical symptoms for different types of arrhythmias, while the exclusion criteria focus on avoiding patients with severe comorbidities or those unable to tolerate surgery. Through this patient screening method, the safety of the study and the accuracy of the data are ensured, thereby enabling a better assessment of the clinical efficacy of the new EasyStars catheter.",{"count":199,"type":19},300,[22],"The primary objective of this study was to evaluate the clinical feasibility, safety, and surgical characteristics of the EasyStars™ High Density Mapping Catheterin in patients with complex arrhythmias.",[203,204,205,25],"Ventricular Tachycardia (VT)","Atrial Tachycardia","Typical Atrial Flutter","2025-07-28",{"date":208,"type":32},"2025-07-31",{"date":210,"type":19},"2025-08-30",{"date":212,"type":19},"2027-12-31",{"name":214,"class":39},"Shanghai MicroPort EP MedTech Co., Ltd.",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":222,"targetDuration":4,"studyType":20,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":65},"100595944","a-clinical-study-on-the-use-of-a-domestically-produced-three-dimensional-cardiac-electrophysiological-mapping-system-combined-with-pressure-monitoring-technology-and-star-mapping-technology-for-the-treatment-of-paroxysmal-atrial-fibrillation-100595944","NCT07039032","A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.","paroxysmal at","Inclusion Criteria:\n\n1. Patient age between 18 and 80 years old, male or non-pregnant female.\n2. Confirmed diagnosis of paroxysmal atrial fibrillation requiring catheter radiofrequency ablation surgery.\n3. Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n1. Post-ablation for atrial fibrillation\n2. Reproductive-age patients who cannot use effective contraception within 12 months of enrolment\n3. Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%\n4. Left atrial thrombus\n5. History of atrial septal defect repair or atrial myxoma\n6. History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack)\n7. History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision)\n8. Patients with acute or severe systemic infection\n9. Patients with severe liver or kidney disease\n10. Patients with significant bleeding tendencies or haematological disorders\n11. Patients with malignant tumours or end-stage diseases\n12. Patients deemed ineligible for this trial by the investigator",{"count":223,"type":19},20,[22],"Validating the safety and efficacy of pressure monitoring technology and star-shaped marking technology for the treatment of paroxysmal atrial fibrillation",[25],[228,229,230],"PFA","PeAF","PFA\u002FRF","2025-06-26",{"date":233,"type":32},"2025-06-27",{"date":235,"type":19},"2025-09-30",{"date":237,"type":19},"2028-12-31",{"name":214,"class":39},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":246,"targetDuration":4,"studyType":20,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":255,"locationsCount":65},"100595716","a-clinical-study-on-the-use-of-a-domestically-produced-cryoablation-system-combined-with-balloon-cryoablation-technology-for-the-treatment-of-paroxysmal-atrial-fibrillation-100595716","NCT07036068","A Clinical Study on the Use of a Domestically Produced Cryoablation System Combined With Balloon Cryoablation Technology for the Treatment of Paroxysmal Atrial Fibrillation","Balloon cryoab","Inclusion Criteria:\n\n1. Patient age between 18 and 80 years old, male or non-pregnant female.\n2. Confirmed diagnosis of paroxysmal atrial fibrillation requiring cryoablation surgery.\n3. Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n1. Patients who have undergone atrial fibrillation ablation surgery\n2. Reproductive-age patients who cannot use effective contraception within 12 months of enrolment\n3. Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%\n4. Left atrial thrombus\n5. Patients who have undergone atrial septal defect repair surgery or atrial myxoma\n6. Patients with cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack)\n7. Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision)\n8. Patients with acute or severe systemic infection\n9. Patients with severe liver or kidney disease\n10. Patients with a significant tendency to bleed or haematological disorders\n11. Patients with malignant tumours or end-stage diseases\n12. Patients deemed ineligible for this trial by the investigator",{"count":223,"type":19},[22],"To validate the safety and efficacy of balloon cryoablation technology and the accompanying disposable intracardiac mapping electrode catheter and adjustable guide sheath for the treatment of paroxysmal atrial fibrillation.",[25],[228,229,230],{"date":233,"type":32},{"date":253,"type":19},"2025-08-31",{"date":212,"type":19},{"name":214,"class":39},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":263,"targetDuration":4,"studyType":20,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":65},"100590869","a-prospective-clinical-study-to-evaluate-the-safety-and-effectiveness-of-pulmonary-vein-isolation-plus-box-isolation-of-fibrotic-areas-with-the-globe-pulsed-field-system-for-treating-patients-with-symptomatic-paroxysmal-or-persistent-atrial-fibrillation-100590869","NCT06973031","A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation","GLOBAL-PF","Key inclusion criteria:\n\n* A diagnosis of recurrent symptomatic paroxysmal or persistent AF\n* Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III\n\nKey exclusion criteria:\n\n* Long-standing persistent AF (sustained \\>12 months)\n* Atrial fibrillation secondary to a reversible cause or of non-cardiac origin\n* History of thromboembolic events within the past six months\n* Myocardial infarction (MI)\u002Fpercutaneous coronary intervention (PCI) within the last three months\n* Any cardiac surgery within the previous six months\n* Prior left atrial ablation or surgical procedure\n* Presence of an implanted cardiac device\n* Body mass index (BMI) \\>40 kg\u002Fm\\^2\n* Left ventricular ejection fraction (LVEF) \\\u003C35%\n* Anterior-posterior left atrial (LA) diameter \\>55mm",{"count":264,"type":19},115,[22],"The study will evaluate the safety and 12-month effectiveness of the Pulmonary Vein Isolation plus Box Isolation of Fibrotic Areas (BIFA) ablation strategy with the Globe Pulsed Field System (Globe PF System) for the treatment of atrial fibrillation.",[25,54],[118],"2025-06-13",{"date":271,"type":32},"2025-06-16",{"date":273,"type":32},"2025-06-10",{"date":275,"type":19},"2028-06",{"name":277,"class":39},"Kardium Inc.",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":285,"sex":15,"minAge":286,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":65},"100589504","multi-centre-based-study-recognition-of-atrial-fibrillation-with-the-corsano-cardiowatch-287-2-system-100589504","NCT06955273","Multi-Centre Based Study Recognition of Atrial Fibrillation With the Corsano CardioWatch 287-2 System","COR-AF","Inclusion Criteria:\n\n* Patients with symptoms indicative of cardiac arrhythmias receiving 24-48 hour ECG holter for home monitoring or in-clinic 12-lead ECG per doctor prescription OR previous diagnosis of arrhythmia presenting to the clinic for routine follow-up evaluation\n* Age ≥ 22 years old\n* Able to provide informed consent.\n* Proficient in written and spoken Dutch or English, defined by self-report of comfort reading, writing, and speaking Dutch or English.\n\nExclusion Criteria:\n\n* Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol;\n* Unable to wear the Corsano CardioWatch 287 due to reasons such as allergic reactions, wounds, amputations etc.;\n* Unable or not willing to receive ECG monitoring;\n* Unable or not willing to sign informed consent;",true,"22 Years",{"count":288,"type":19},350,"This concerns a multi-center, single-arm, diagnostic accuracy study. In this study, a wristband that monitors heart rythm is assessed in clinical and free living conditions. The performance of the wristband in detecting atrial fibrillation and normal sinus rhythms will be compared to a short 12-lead ECG or 24-hour holter.\n\nTo ensure that both patients with and without atrial fibrillation are included whilst limiting the burden on patients and hospital staff, four groups of patients are being recruited:\n\n* Group A: patients receiving an ECG holter at the outpatient clinic for 24-48 hours of remote monitoring\n* Group B: patients diagnosed with (paroxysmal) AF presenting to the clinic for routine follow-up evaluation.\n* Group C: patients diagnosed with (paroxysmal) AF registered in a patient organisation for patients with AF.\n* Group D: patients receiving a 12-lead ECG at the outpatient clinic as standard of care.\n\nThe secondary outcomes of the study focus on assessing the primary outcomes in light of demographic subgroups, patient physical activity and the signal quality index.",[112,25],[292,293,294,295,296,297,298],"wristband","wearable","atrial fibrillation","holter","ecg","remote monitoring","validation","2025-04-30",{"date":301,"type":32},"2025-05-02",{"date":303,"type":19},"2025-05-01",{"date":305,"type":19},"2026-01",{"name":307,"class":39},"Corsano Health B.V."]